Influenza Vaccine Tetra Myl (B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202)

Influenza Vaccine Tetra Myl is used to prevent influenza B virus infections, a major cause of seasonal flu.

• Influenza B (B/Phuket/3073/2013-like strain): prevents illness and complications in at‑risk populations.
• Influenza B (B/Austria/1359417/202 strain): reduces incidence of disease in individuals receiving the vaccine.
• Seasonal influenza caused by B lineages: lowers overall community transmission when used in vaccination programs.

• Influenza Vaccine Tetra Myl contains inactivated or recombinant antigens from the B/Phuket/3073/2013-like and B/Austria/1359417/202 influenza B viruses. After intramuscular or subcutaneous injection, the antigens are taken up by antigen‑presenting cells, which stimulate B‑cell and T‑cell responses, leading to the production of strain‑specific neutralising antibodies that confer active immunity against subsequent exposure to the matching influenza B viruses.

Common and serious adverse reactions may occur after administration of Influenza Vaccine Tetra Myl.

Common Side Effects

• Injection site pain
• Redness at the injection site
• Swelling at the injection site
• Low‑grade fever

Serious or Rare Side Effects

• Anaphylaxis
• Guillain‑Barré syndrome
• Seizures
• High‑grade fever

Before administering Influenza Vaccine Tetra Myl, consider the following precautions.

• Assess allergy history: avoid in persons with severe hypersensitivity to any vaccine component.
• Defer vaccination: postpone in individuals with acute moderate or severe illness.
• Monitor after injection: observe for at least 15 minutes for immediate reactions.
• Use caution in immunocompromised patients: vaccine may elicit reduced immune response.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Influenza Vaccine Tetra Myl may interact with certain medications or other vaccines.

Major Interactions (Avoid)

• Live attenuated vaccines: avoid concurrent administration due to potential interference.
• Immunoglobulin therapy: may reduce vaccine effectiveness if given within 2 weeks before or after vaccination.

Moderate Interactions (Monitor Closely)

• Antipyretics (acetaminophen, ibuprofen): may blunt antibody response if taken prophylactically.
• Immunosuppressive drugs (e.g., corticosteroids, chemotherapy): may diminish immune response, monitor seroconversion.
• Antihistamines: may mask early allergic signs, observe patient closely.